Frequently Asked Questions

What is RENOVÓ Regenerative Biologics?

RENOVÓ is a regenerative biologics and clinical peptide supplier based in Miami Beach, Florida, serving licensed practitioners, clinics, and medical spas. The platform spans four categories: umbilical cord–derived exosomes, Wharton's jelly, stem cell conditioned media, and a 53-presentation clinical peptide portfolio.

RENOVÓ's position is that a supplier's value is in the framework it gives a clinic, not in the vial. Partners receive protocol architecture, selection logic, and documentation alongside product — the reasoning that determines which formulation belongs in which clinical context.

Where is RENOVÓ located and where does it ship?

RENOVÓ operates from Miami Beach, Florida, and ships throughout the United States and internationally. Domestic options are standard, two-day, overnight, and frozen cold-chain. International options are standard, expedited, and frozen two-day. Cold-chain shipping is reserved for cryopreserved formulations, where it is a requirement rather than a precaution.

Where are RENOVÓ's biologics sourced from?

All biologic formulations are derived from human umbilical cord tissue collected at full-term Caesarean-section births in the United States. Donors are screened against a full infectious disease panel and are mRNA-unvaccinated. Vaginal-birth tissue is not used, as the collection environment cannot be controlled to the same standard.

Exosome formulations are derived from two distinct source environments: Wharton's jelly, which carries connective tissue and extracellular matrix signalling, and endothelial stem cells from cord blood, which carry vascular and systemic signalling. These are categorised separately because their signalling orientation is fundamentally different — not because one is stronger.

Does RENOVÓ provide a Certificate of Analysis?

Yes. A COA accompanies every biologic lot, covering particle count and size distribution, surface marker confirmation (CD9, CD63, CD81), sterility, endotoxin, mycoplasma, and full serology. Peptide presentations are verified to a minimum 99% purity by high-performance liquid chromatography with identity confirmed by mass spectrometry.

COAs are published rather than supplied on request. A supplier that will not put its lot data in front of you before you order is telling you something.

Are RENOVÓ products FDA approved?

No, and RENOVÓ does not claim otherwise. Manufacturing takes place in FDA-registered, CGMP-compliant United States facilities. Facility registration is a manufacturing status, not a product approval, and the two are frequently conflated in this industry — sometimes carelessly, sometimes deliberately.

RENOVÓ formulations are not FDA-approved drugs and are not intended to diagnose, treat, cure, or prevent any disease. Several peptide compounds in the portfolio are not approved for human therapeutic use in the United States. Regulatory status varies by jurisdiction and changes over time. Determining the legality, appropriateness, and clinical justification of any formulation for any individual patient is the responsibility of the treating practitioner.

What is the difference between exosomes, Wharton's jelly, and conditioned media?

Exosomes are membrane-bound extracellular vesicles that carry protected biological signal — growth factors and signalling proteins delivered inside a lipid membrane the body recognises. Wharton's jelly is the structural matrix itself: hyaluronic acid, collagen types I and III, and the architectural environment into which signalling is delivered. Conditioned media is the full soluble secretome — the complete set of factors a cell population released, without vesicular packaging.

The practical distinction is one of register. Exosomes deliver signal into an environment. Wharton's jelly supplies the environment. Conditioned media provides the broadest immediate paracrine availability. Full protocols frequently combine them.

What is the difference between a peptide and a biologic?

A peptide is a single defined amino acid sequence, synthesised to specification, acting on one receptor family or one axis. It is quantifiable to the milligram, reproducible vial to vial, and titratable deliberately across a course of weeks.

A biologic is a native population of signalling factors present in the ratios the source tissue produced them. It operates through many coordinated mechanisms rather than one, is characterised by particle count and marker profile rather than a single molecular weight, and is delivered as an environment rather than a dose.

Neither substitutes for the other. RENOVÓ's sequencing logic is to establish the biological environment with a biologic first, then apply a peptide for the specific axis the environment cannot address on its own.

How are RENOVÓ's exosome formulations numbered?

The number is particle count in billions, not a ranking. EXO-30 and EXO-50 are Wharton's jelly–derived and oriented to connective tissue and surface contexts. EXO-90 and EXO-180 are endothelial stem cell–derived and oriented to vascular, immune, and neurovascular contexts. EXO-180 is cryopreserved rather than lyophilised and requires cold-chain handling.

A higher number is not a better product. It is a different source environment with a different signalling profile. Selection begins with clinical context, not concentration.

What peptides does RENOVÓ carry?

Fifty-three presentations across seven mechanism classes: metabolic and weight management, healing and recovery, growth hormone axis, longevity and cellular, cognitive and mood, hormone support, and oral capsule formulations. Single-compound vials, dual-compound vials, and multi-compound stack presentations are available, with multiple strengths per compound family so titration schedules can be built without switching product line mid-protocol.

The full category breakdown is published in the Peptide Reference.

Who can buy from RENOVÓ?

Peptide formulations and clinical-only biologics are supplied to licensed healthcare practitioners, clinics, and medical spas operating within an established patient relationship. A subset of biologic formulations is available in consumer contexts. Peptides are not offered for sale or distribution to the general public.

Does RENOVÓ offer wholesale or clinical partnership pricing?

Yes. Clinical accounts receive wholesale pricing across the full platform, with no minimum order quantity. Portfolio breadth is maintained deliberately so a practitioner is never forced to redesign a protocol around what a supplier happens to stock.

Partnership includes protocol frameworks, selection guidance, published lot documentation, and clinical reference material — the working standard, not just the supply line.

How do I become a RENOVÓ clinical partner?

Contact Dimitri Nicholas directly at Dimitri@renovobiologics.com or (937) 214-2202, or apply through the Clinical Partners page. Verification of licensure is required before a clinical account is opened.

How should RENOVÓ formulations be stored?

Lyophilised vials — both peptide and biologic — are ambient-stable through transit and best held refrigerated for longer periods, protected from light and moisture. Once reconstituted, storage moves to 2–8°C and stability becomes finite; reconstituted vials should not be frozen, as freeze-thaw cycling is the fastest route to degradation. Cryopreserved formulations require frozen handling from receipt. Oral capsules require no reconstitution and are stored sealed at ambient temperature.